Psoriasis Vulgaris Clinical Trial
Official title:
Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis
Psoriasis is a common immune mediated inflammatory skin disease characterized by red heavily
scaled plaques. Anthralin (1,8-dihydroxy-9-anthrone) which was introduced over 80 years ago
has shown excellent efficacy in the management of psoriasis.Although anthralin is remarkably
effective in the management of psoriasis, its side effects are equally disturbing. Its use is
messy as it stains the skin, clothing, and any furniture that it may come in contact with.
Further, anthralin has irritating, burning, brown discoloration and necrotizing effect on the
normal and the diseased skin. This troublesome profile has discouraged wide-spread use of the
drug.
Ethosomes are attractive vesicular carriers mainly composed of phospholipids, ethanol and
water. The intriguing features of ethosomes are due to their high ethanol content which
facilitate their penetration through stratum corneum and target deep skin layers. This is
advantageous over conventional liposomes which have limited penetration through the skin and
remain confined in the upper layer of the stratum corneum. Compared to liposomes, ethosomes
had greater retention of methotrexate into the skin for a longer period of time, suggesting
better therapeutic outcome.
Psoriasis is a common immune mediated inflammatory skin disease characterized by red heavily
scaled plaques. Anthralin (1,8-dihydroxy-9-anthrone) which was introduced over 80 years ago
has shown excellent efficacy in the management of psoriasis.Anthralin mechanism of action
involves inhibition of the proliferation of keratinocytes. Further, accumulation of anthralin
inside the mitochondria impairs energy supply to the cell, probably due to the free radicals
resulting from oxidation of the drug. Anthralin also interferes with the replication of DNA
and slows down the extreme cell division that occurs in psoriatic plaques. Although anthralin
is remarkably effective in the management of psoriasis, its side effects are equally
disturbing. Its use is messy as it stains the skin, clothing, and any furniture that it may
come in contact with. Further, anthralin has irritating, burning, brown discoloration and
necrotizing effect on the normal and the diseased skin. This troublesome profile has
discouraged wide-spread use of the drug.
Ethosomes are attractive vesicular carriers mainly composed of phospholipids, ethanol and
water. The intriguing features of ethosomes are due to their high ethanol content which
facilitate their penetration through stratum corneum and target deep skin layers. This is
advantageous over conventional liposomes which have limited penetration through the skin and
remain confined in the upper layer of the stratum corneum. Compared to liposomes, ethosomes
had greater retention of methotrexate into the skin for a longer period of time, suggesting
better therapeutic outcome.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03669757 -
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis
|
Phase 1 | |
Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT03584360 -
Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin
|
Phase 2 | |
Recruiting |
NCT04994951 -
Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.
|
Phase 2 | |
Completed |
NCT02888236 -
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
|
Phase 2 | |
Completed |
NCT02533973 -
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
|
Phase 4 | |
Completed |
NCT02193815 -
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
|
Phase 1 | |
Completed |
NCT01946386 -
A Vasoconstriction Study With LEO 90100
|
Phase 1 | |
Completed |
NCT02004847 -
Blue Light for Treating Psoriasis Vulgaris
|
N/A | |
Recruiting |
NCT01443338 -
Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
|
Phase 4 | |
Completed |
NCT01188928 -
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
|
Phase 3 | |
Completed |
NCT00764751 -
Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
|
Phase 2 | |
Completed |
NCT00236171 -
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test
|
N/A | |
Completed |
NCT04541329 -
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
|
Phase 4 | |
Completed |
NCT06064084 -
Incretin Effect in Patients With Psoriasis and Controls
|
||
Not yet recruiting |
NCT06398106 -
Proactive TDM Versus Standard Use of Biologics in Psoriasis
|
Phase 4 | |
Recruiting |
NCT05892640 -
Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis
|
N/A | |
Recruiting |
NCT05390515 -
Psoriatic Immune Response to Tildrakizumab
|
Phase 4 | |
Recruiting |
NCT04950218 -
The Psoriasis Echo Study
|
||
Completed |
NCT05184348 -
Plexin B2 Gene Expression and Polymorphisms in Psoriasis
|
Phase 1 |